A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

The Nova 301 trial will see a vaccine developed by pharmaceutical firm Moderna and 2,500 volunteers in the UK taking part. Like Moderna's vaccine used in the COVID-19 vaccination campaign ...

The plot has thickened in the Justin Trudeau-Heinz ketchup controversy, as consumers with bottles that say "Product of USA" question how Canadian the popular condiment really is. Kraft Heinz took ...

As part of a novel initiative to combat plastic waste, UK households will be rewarded for returning empty bottles to their local supermarkets. This deposit return scheme, already implemented in ...

After years of lugging around wide-mouth insulated bottles (and not-so-gracefully chugging them at the gym), the brand’s proprietary hidden straw truly spoke to me. If you’ve ever tried ...

While the U.S. already has vaccines against H5 viruses in its Strategic National Stockpile, they are based on older technology. HealthDay News — The U.S. Department of Health and Human Services (HHS) ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...